A team from the Institute of Scientific Research in Tokyo used iPS cells to construct 'mini-liver' organoids (iHSO) containing hepatocytes and hepatic stellate cells, revealing for the first time the mechanism of cell-to-cell communication through the ICAM-1/IL-1β signaling pathway during liver fibrosis. This model can simulate the progression of fibrosis following liver injury and has been used for high-throughput drug screening, aiming to develop targeted therapies that do not require liver transplantation. This technology not only provides new ideas for liver disease treatment but also demonstrates the value of organoids in modeling complex age-related diseases, advancing personalized anti-aging research.